C. diff (Pseudomembranous Colitis)

Clostridium difficile infections (CDI) continue to be a great burden in the United States. In 2015, the CDC estimated there were close to 500,000 cases and 29,000 deaths within 30 days of diagnosis. The EvidenceCare C. diff pathway assists providers with appropriate prevention strategies, diagnosis, and treatment of CDI. A treatment algorithm is included based on your patient’s severity of disease and number of recurrences. Optimal antibiotic selection for each subtype of CDI is included. There is a discussion on the evidence related to probiotic and fecal microbiota transplant (FMT) use to prevent recurrence of CDI. Evidence is included from the American College of Gastroenterology’s (ACG) 2013 Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections as well as the 2010 IDSA Clinical Practice Guideline for Clostridium difficile.

Christina Surawicz, MD, MACG
Read More

You May Also Like These Protocols


The EvidenceCare Seizure pathway provides treatment guidelines for management of seizures in the hospital setting and includes recommendations for new…

Learn More